Contact the Host for event and ticket information.

This event has ended!

View current events hosted by

MaRS Drug Development Discussion Series:
Disease Specific Epitopes Immunotherapies

Monday, July 6, 2009 from 12:00 PM to 1:00 PM (ET)

Toronto, Canada

MaRS Drug Development Discussion Series: Disease Specific...

Ticket Information

Type End     Quantity
General Admission Ended Free  
Waiting List (You will be contacted on a first-come, first-served basis when more spots open up) Ended Free  

Event Details

The Drug Development Discussion Group (DDD Group) is an informal moderated forum bringing together research professionals and clinicians interested in drug development. At this session, Dr. George Adams of Amorfix will discuss predicting and verifying disease specific epitopes on misfolded proteins and the development of DSE immunotherapies (antibodies & vaccines).

Speaker: Dr. George Adams (Amorfix)

Each session has a 30-minute presentation and a 45-minute moderated discussion. For more information on this series or to register for a specific event please contact MaRS at events@marsdd.com.

Generously supported by:

ABOUT THE SPEAKER

Dr. George Adams

Dr. George Adams, Chief Executive Officer and Director, Amorfix. Dr. Adams is a scientist and serial entrepreneur providing leadership, senior management and strategic guidance to life sciences companies in roles including CEO or board participation. Dr. Adams was the President and CEO of the Innovations Foundation from 1999 until 2004, where he was involved in creating companies and commercializing technologies. Prior to this, he held research and executive positions with Boston Scientific Inc, Pfizer Inc., Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood Transfusion Service.  He has also been a founding angel investor in six start-up companies in Canada and the United States.  He has been instrumental in obtaining venture financing for 24 companies who have raised $85 million and has been a Director of 10 venture capital funds and 8 start-up companies. Dr. Adams has 124 publications including 9 invited reviews, 26 full papers and 3 patents. He is a past President of the Canadian Biomaterials Society. He has been a reviewer for numerous scientific journals, national granting agencies and several national and provincial centres of excellence. He has been a principal investigator for over $40 million in private and publicly-funded research and development. Dr. Adams is a graduate of the Rotman School of Management Director's Education Program.